Sotatercept in Patients With Pulmonary Arterial Hypertension: An Updated Meta-Analysis of Randomized Controlled Trials
Authors:
- Mushood AhmedMAMushood Ahmed
- Ayça ZalAZAyça Zal
- Zahra ZahiriZZZahra Zahiri
- Hirad MeshkatiHMHirad Meshkati
- Hadiah AshrafHAHadiah Ashraf
- Eman Ibrahim Elzain HassanEHEman Ibrahim Elzain Hassan
- Hritvik JainHJHritvik Jain
- Faizan AhmedFAFaizan Ahmed
- Himaja Dutt ChigurupatiHCHimaja Dutt Chigurupati
- Sivaram NeppalaSNSivaram Neppala
- 18 August 2026
- journal article
- review article
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 33 (5) , e453-e460
Abstract
Was not provided for this article.Keywords
This publication has 18 references indexed in Scilit:
- Efficacy and safety of sotatercept in pulmonary arterial hypertension: a meta-analysis of randomized controlled trialsExpert Review of Respiratory Medicine, 2025
- Clinical outcomes and safety of sotatercept in pulmonary arterial hypertension: A systematic review and meta-analysis of randomized controlled trialsVascular Pharmacology, 2025
- Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for DeathNew England Journal of Medicine, 2025
- Global, regional, and national burden of pulmonary arterial hypertension, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021The Lancet Respiratory Medicine, 2024
- Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial HypertensionNew England Journal of Medicine, 2023
- An emerging class of new therapeutics targeting TGF, Activin, and BMP ligands in pulmonary arterial hypertensionDevelopmental Dynamics, 2022
- Sotatercept for the Treatment of Pulmonary Arterial HypertensionNew England Journal of Medicine, 2021
- The PRISMA 2020 statement: an updated guideline for reporting systematic reviewsBMJ, 2021
- RoB 2: a revised tool for assessing risk of bias in randomised trialsBMJ, 2019
- Measuring inconsistency in meta-analysesBMJ, 2003